Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 18/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231019 | 0.91 | FFAR1 (0.56) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL224879 | 0.84 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL225598 | 0.84 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL231113 | 0.82 | FFAR1 (0.54) | FFAR1 | |
| SCHEMBL230950 | 0.81 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL232151 | 0.79 | FFAR1 (0.48) | FFAR1 | |
| SCHEMBL231174 | 0.77 | FFAR1 (0.57) | FFAR1CYP2C9CYP2B6SLCO1B3 | |
| SCHEMBL224951 | 0.76 | FFAR1 (0.56) | FFAR1 | |
| SCHEMBL223927 | 0.75 | FFAR1 (0.57) | FFAR1 | |
| SCHEMBL231177 | 0.74 | FFAR1 (0.76) | FFAR1CYP2C9CYP2B6SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | REN, PKD1, AKR1C3 | FFAR1 287/4885TRPV4 1309/4885CYP2C9 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.